Literature DB >> 11443745

Association of p53 and BCL-2 expression with Epstein-Barr virus infection in the cancers of head and neck.

H J Yang1, Y J Cho, H S Kim, M S Chang, M W Sung, W H Kim.   

Abstract

BACKGROUND: Reports that have both evaluated the site-specific Epstein-Barr virus (EBV) infection and compared it with the expression of the EBV-related proto-oncogenes and tumor suppressor genes in the various cancers of head and neck are scarce.
METHODS: Thirty-eight nasopharyngeal carcinoma (NPC) cases, 32 oropharyngeal or hypopharyngeal carcinoma (OPC/HPC) cases, and 93 laryngeal carcinoma (LC) cases were evaluated with in situ hybridization on EBV-encoded small RNA (EBER) and immunohistochemical assessments of the p53, bcl-2, and epidermal growth factor receptor (EGFR) by use of formalin-fixed paraffin-embedded tissue array slides.
RESULTS: The expression of viral EBERs was observed in more than two thirds (71.1%) of the NPC cases. In contrast, only 1 case of OPC and none of the HPC or LC cases exhibited EBV positivity. In the nonkeratinizing NPC, the EBV positivity was significantly associated with both frequent p53 overexpression (p =.033) and bcl-2 expression (p =.001). In the EBV-positive nonkeratinizing NPC, a correlation between p53 overexpression and the tumor infiltration lymphocyte (TIL) density was noted (p =.012).
CONCLUSIONS: A site-specific expression of viral EBER was demonstrated in the head and neck cancers, which suggests an important role for both p53 and bcl-2 in the carcinogenesis of an EBV-infected NPC. The correlation between p53 overexpression and the TIL density in the EBV-infected NPC suggests that the product of a lymphoepithelial interaction, such as A20, can induce a dysfunctional p53 protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443745     DOI: 10.1002/hed.1089

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Association of Protein Expression p53 Mutants with Regional Lymph Gland Status on type III Carcinoma Nasofaring Patients.

Authors:  Riza Aswarin; Muhtarum Yusuf; M S Wiyadi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-05-21

Review 2.  Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.

Authors:  Josephine Chou; Yu-Ching Lin; Jae Kim; Liang You; Zhidong Xu; Biao He; David M Jablons
Journal:  Head Neck       Date:  2008-07       Impact factor: 3.147

3.  Clinical and molecular prognostic factors in operable laryngeal cancer.

Authors:  Konstantinos Vlachtsis; Angelos Nikolaou; Konstantinos Markou; George Fountzilas; Ioannis Daniilidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

4.  Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers.

Authors:  Warut Tulalamba; Tavan Janvilisri
Journal:  Int J Cell Biol       Date:  2012-03-05

5.  Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis.

Authors:  Chung-Feng Hwang; Li-Yen Shiu; Li-Jen Su; Wei-Sheng Wang; Shun-Chen Huang; Tai-Jan Chiu; Chao-Cheng Huang; Yen-Yi Zhen; Hsin-Ting Tsai; Fu-Min Fang; Tai-Lin Huang; Chang-Han Chen
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

6.  Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation of NF-κB pathway.

Authors:  Shu-Peng Chen; Qi Yang; Chan-Juan Wang; Long-Juan Zhang; Yi Fang; Fang-Yong Lei; Shu Wu; Li-Bing Song; Xiang Guo; Ling Guo
Journal:  Mol Cancer       Date:  2014-08-22       Impact factor: 27.401

7.  Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers.

Authors:  Zeyi Deng; Takayuki Uehara; Hiroyuki Maeda; Masahiro Hasegawa; Sen Matayoshi; Asanori Kiyuna; Shinya Agena; Xiaoli Pan; Chunlin Zhang; Yukashi Yamashita; Minqiang Xie; Mikio Suzuki
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.